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Abstract: Inflammatory bowel disease (IBD) is a complex class of immune disorders. Unfortunately,
a treatment for total remission has not yet been found, while the use of natural product-based
therapies has emerged as a promising intervention. The present study was aimed to investigate the
anti-inflammatory effects of the algal meroterpene 11-hydroxy-11-O-methylamentadione (AMT-E) in
a murine model of dextran sodium sulphate (DSS)-induced colitis. AMT-E was orally administered
daily (1, 10, and 20 mg/kg animal) to DSS treated mice (3% w/v) for 7 days. AMT-E prevented
body weight loss and colon shortening and effectively attenuated the extent of the colonic damage.
Similarly, AMT-E increased mucus production and reduced myeloperoxidase activity (marker for
anti-inflammatory activity). Moreover, the algal meroterpene decreased the tumor necrosis factor
(TNF)-α, interleukin (IL)-1β, and IL-10 levels, and caused a significant reduction of the expression of
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Our results demonstrate the
protective effects of AMT-E on experimental colitis, provide an insight of the underlying mechanisms
of this compound, and suggest that this class of marine natural products might be an interesting
candidate for further studies on the prevention/treatment of IBD.
Keywords: marine meroterpenoids; macroalgae; intestinal inflammation; experimental colitis;
cytokines; COX-2; iNOS
1. Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are two typical forms of inflammatory intestinal
disease belonging to inflammatory bowel disease (IBD) [1], which affect millions of people worldwide
and carry a widespread health hazard in modern society [2]. IBD is characterized by chronic and
recurrent inflammatory disorders of the gastrointestinal tract [3]. Despite many years of extensive
research, the aetiology and pathogenesis of IBD is not completely understood. It probably involves a
complex interaction of several factors, including genetic susceptibility, immune disorders, bacterial
flora within the intestinal environment, and environmental factors [4]. Therefore, the development of
new, effective, and well-tolerated drugs for IBD therapy is necessary. Various models of experimental
IBD have been developed to investigate the pathogenesis of this disease and may be used to test
innovative approaches for therapy [5]. Among these models, experimental colitis induced by dextran
sulphate sodium (DSS) has been widely used because it affords a high degree of uniformity and
reproducibility of most lesions in the distal colon, and after 7 days of DSS administration the intestinal
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immune system is activated to generate, in a coordinated form, pro-inflammatory/anti-inflammatory
cytokines [6]. The pro-inflammatory cytokines amplify the inflammatory response by activating a
cascade of immune cells such as neutrophils and macrophages. Infiltration of neutrophils results
in the production of large amounts of cytotoxic reactive oxygen species, nitrogen metabolites,
and lytic enzymes, which lead to severe inflammatory tissue injury, including mucosal disruption and
ulceration [7].
Macroalgae produce a wide variety of bioactive compounds that offer great opportunities
in the biomedical field [8–10]. Although most research on the pharmacological potential of algal
natural products has focused on cytotoxic and antimicrobial activities [8,9,11], recent studies are also
disclosing interesting properties of algae-derived extracts and natural products as anti-inflammatory
agents [12–15]. Thus, we have recently described the in vitro anti-inflammatory activity of a
series of meroterpenoids isolated from the brown alga Cystoseira usneoides [16,17]. In particular,
the meroditerpene 11-hydroxy-11-O-methylamentadione (AMT-E) (Figure 1), which is one of the major
natural products of this alga, showed significant activity as an inhibitor of the production of the
pro-inflammatory cytokine TNF-α in LPS-stimulated THP-1 human macrophages [16].
The promising in vitro activity exhibited by AMT-E led us to investigate the potential in vivo
anti-inflammatory effect of this natural product on the experimental colitis induced by DSS. We have
found that AMT-E exerts intestinal anti-inflammatory activity in the colitis by increasing mucus
production, inhibiting neutrophil infiltration, down-regulating TNF-α, IL-1β, and IL-10, as well as
suppressing COX-2 and iNOS expression in the mouse colon tissue.
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using  the DSS model of acute  intestinal  inflammation.  It  is worth noting  that neither DSS nor  the 
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animals (p < 0.001) (Table 1 and Figure 2a,b). This effect is indicative of the presence of inflammation. 
AMT‐E treatments modified this effect and the highest dose of the compound (20 mg/kg) was able to 
significantly prevent DSS‐induced colon  shortening  (p < 0.01)  (Table 1 and Figure 2e). Moreover, 
mice that were treated with DSS showed a progressive loss of body weight, with fluctuations typical 
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li r i e s, and heart, which are highly susceptible to drug toxicity. How ver, as show
in Table 1, mice that w re treated with D S showed a marked colon shortening in l ti
. ) ( i , . is eff ct is i icati e of the prese ce of infla atio .
- ifi t is effect and the highest dose of the compound (20 mg/kg) w s able
to significantly pr vent DSS-induced c lon shorte ing (p < .01) (Table 1 and Figure 2e). re er,
te ith SS showed a progres ive loss of body weight, with fluctuations typical of
this type of exp riment, during the 7 days that the study lasted (Figure 2f). Mice treated with AMT-E
were protect d from this marked loss of body weight, with significant response from day three to the
end, and for the three doses ested.
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Table 1. Effects of AMT-E (1, 10, and 20 mg/kg p.o.) on colonic length in dextran sodium sulphate
(DSS)-treated mice.







Colonic length (cm) 7.93 ˘ 0.16 6.02 ˘ 0.12 +++ 6.19 ˘ 0.10 7.00 ˘ 0.14 7.03 ˘ 0.16 **
a Sham group, receiving vehicle; b Group treated with DSS (3%) in drinking water, for 7 consecutive days;
c Treated with DSS (3%) in drinking water and with AMT-E (1, 10, or 20 mg/kg, p.o.), for 7 consecutive days.
Data are means ˘ S.E.M and were analysed by one-way ANOVA followed by Tukey test for comparison











Colonic length (cm)  7.93 ± 0.16  6.02 ± 0.12 +++  6.19 ± 0.10  7.00 ± 0.14  7.03 ± 0.16 ** 
a Sham group, receiving vehicle; b Group treated with DSS (3%) in drinking water, for 7 consecutive 
days;  c Treated with DSS  (3%)  in drinking water and with AMT‐E  (1, 10, or 20 mg/kg, p.o.),  for 7 
consecutive days. Data  are means  ±  S.E.M  and were  analysed by one‐way ANOVA  followed by 
Tukey test for comparison between groups. +++ p < 0.001 vs. Sham group; ** p < 0.01 vs. DSS group. 
 












medial‐distal area of  the colon,  this was also evident after  the microscopic analysis  involving all 
Figure 2. 11-hydroxy-11-O-methylamentadione (AMT-E) protect mice against dextran sodium sulphate
(DSS)-induced colitis. (a–e) Representative macroscopic appearance of the colon in (a) Sham group
(b) mice treated with DSS and (c–e) mice receiving DSS plus AMT-E (1, 10, and 20 mg/kg p.o.,
respectively); (f) Change in bodyweight during the study. Data are expressed as the means ˘ SEM.
Statistical significance between Sham and DSS groups was determined by Student’s t test. The statistical
differences between DSS and treatments groups were determined by oneway ANOVA followed by
Bonferroni post-hoc test. + p < 0.05 and ++ p < 0.01 vs. Sham group; * p < 0.05, ** p < .01 and
*** p < 0.001 vs. DSS group.
2.2. AMT-E Alleviates Microscopic Colon Damage and Increases ucus Production
Histological examination and results from the histopathological score for all groups are shown in
Figure 3 and Table 2. Colons from Sham mice revealed typical features of normal structure (Figure 3a).
Consistent with the macroscopic changes, where DSS-treated mice showed inflammation in the
medial-distal area of the colon, this was also evident after the microscopic analysis involving all
layers of the bowel wall (score 3.93 ˘ 0.2, Table 2); extensive granulation tissue with the presence of a
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massive neutrophilic infiltration, fibroblasts and lymphocytes was also apparent, mainly in the mucosa
and submucosa; necrosis of epithelium, distortion of crypts, and partial destruction of the glands
were also detected (Figure 3c); Alcian blue staining, which detects acid mucin-positive goblet cells,
revealed remarkable mucin depletion in ulcerative areas of DSS-treated animals (Figure 3d) compared
with Sham mice (Figure 3b). By contrast, the histological sections of the AMT-E-treated animals
(Figure 3e,g,i) showed an improvement in the microscopic features of colitis at all the doses used,
evidenced by a preservation of the colonic mucosa structure and a reduction of inflammatory cells in
the lamina propria when compared to DSS group. Moreover, Alcian blue-positive goblet cells were
clearly observed in preserved regions of the mucosal layer in mice treated (Figure 3f,h,j). This analysis
provides a score of 2.34 ˘ 0.1, 2.12 ˘ 0.2, and 1.82 ˘ 0.2 for AMT-E doses of 1, 10, and 20 mg/kg























Figure 3. 11-hydroxy-11-O-methylamentadione (AMT-E) administration attenuate microscopic colon
damage induced by dextran sulfate sodium (DSS); this effect is detected in Haematoxylin/Eosin and
also in Alcian Blue stain sections where positive goblet cells were more clearly observed in preserved
regions of the mucosal layer in mice treated with different dose of AMT-E. Histological appearance of
samples taken from middle to distal colon of mice: (a,b) Sham group; (c,d) DSS group; (e,f) DSS plus
AMT-E (1 mg/kg, p.o.); (g,h) DSS plus AMT-E (10 mg/kg, p.o.) and (i,j) DSS plus AMT-E (20 mg/kg,
p.o.). Original magnification 200ˆ.
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Table 2. Effects of AMT-E on Histological Score in the dextran sodium sulphate (DSS) model.
Treatments Sham DSS AMT-E (1 mg/kg) AMT-E (10 mg/kg) AMT-E (20 mg/kg)
Colitis score 0 3.93 ˘ 0.2 * 2.34 ˘ 0.1 † 2.12 ˘ 0.2 † 1.82 ˘ 0.2 †
The criteria used for the histopathological scoring and immunostaining evaluation of colonic mucosa are
described in the Experimental Section. Data are expressed as the means ˘ SEM. * p < 0.05 versus respective
Sham group. † p < 0.05 versus DSS group.
2.3. AMT-E Attenuates MPO Levels in DSS-Induced Colitis in Mice
The histopathology study indicated that a mechanism underlying the protective effects of AMT-E
involved a reduced infiltration of inflammatory cells into the colonic mucosa. Thus, colon inflammation
was quantitatively evaluated by MPO activity. As shown in Figure 4, DSS induced a significant increase
in colon MPO activity from 0.07 ˘ 0.003, a basal concentration, to 0.11 ˘ 0.006 U/mg tissue (p < 0.001
vs. Sham group) after 7 days of DSS administration. The treatment with AMT-E at the doses of 10
and 20 mg/kg significantly suppressed the degree of polymorphonuclear neutrophil infiltration in
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Figure 4. 11-hydroxy-11-O-methylamentadione (AMT-E) administration reduces leukocyte infiltration.
Myeloperoxidase activity (MPO, U/mg tissue) was quantified in mice treated with DSS alone or mice
receiving DSS plus AMT-E (1, 10, and 20 mg/kg, p.o.). The Sham group received vehicle in an equal
volume. Data are expressed as the means ˘ SEM. Statistical significance between Sham and DSS groups
was determined by Student’s t test. The statistical differences between DSS and AMT-E treated groups
were determined by oneway ANOVA followed by Bonferroni post-hoc test. +++ p < 0.001 vs. Sham
group. ** p < 0.01 vs. DSS group.
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i t e colon ti sues from D S-treated mice compared to that in control animals. Fu the mor ,
the administration of AMT-E at a d se of 20 m /kg significantly reduced the levels of these cytokines
by 60% (p < 0.01) and 67% (p < 0.001), r spectively, with respect to DSS g oup (Figure 5a,b).
As regards IL-10, this cytokine was up-regulated in DSS-treated mice compared with Sham group.
Interestingly, 10 and 20 mg/kg of AMT-E resulted i a significant decrease of IL-10 valu s compared
with DSS group (Figure 5c).
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The effect of AMT‐E on  the expression  levels of COX‐2 and  iNOS  in  cytosolic extracts  from 
colonic  mucosa  was  evaluated  by  Western  blot  analysis.  The  expression  of  both  proteins  was 
significantly  increased  in the colon tissues from DSS‐treated mice compared with those  in control 





of COX‐2  and  iNOS  enzymes  in DSS‐induced  colitis.  (a) Representative western  blot  analysis  of 
COX‐2 (n = 5) and iNOS (n = 4) proteins; (b) Densitometric data were studied following normalization to 
the  control  (housekeeping  gene,  β‐Actin).  Data  are  expressed  as  the  means  ±  SEM.  Statistical 
significance  between  Sham  and DSS  groups was  determined  by  Student’s  t  test.  The  statistical 
differences between DSS and AMT‐E treated groups were determined by oneway ANOVA followed 
by Bonferroni post‐hoc test. ++ p < 0.01 vs. Sham group. * p < 0.05 and ** p < 0.01 vs. DSS group. 
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- i f - i i l ic cosa
ef ect of AMT-E on the expression levels of COX-2 and iNOS in cytosolic extra ts from colonic
mucosa was evalu ted by Western blot analysis. The expression of both proteins was sign ficantly
increased in the colon tissues fr m DSS-treated mice compared with those in con rol mice (p < 0.01).
However, administration of AMT-E significantly reduced the DSS-i duced expression of COX-2 an





of  colonic  tissue  in DSS‐induced  colitis.  (a)  TNF‐α  levels  (ng/mg  tissue);  (b)  IL‐β  levels  (ng/mg 







The effect of AMT‐E on  the  xpression  levels of COX‐2 and  NOS  in  cytosolic extracts  from 
colonic  mucosa  was  evaluated  by  Western  blot  analysis.  The  expression  of  both  proteins  was 
significantly  increased  in the colon tissues from DSS‐treated mice compared with those  in control 





of COX‐2  and  iNOS  enzymes  in DSS‐induced  colitis.  (a) Representative western  blot  analysis  of 
COX‐2 (n = 5) and iNOS (n = 4) proteins; (b) Densitometric data were studied following normalization to 
the  control  (housekeeping  gene,  β‐Actin).  Data  are  expressed  as  the  means  ±  SEM.  Statistical 
significance  between  Sham  and DSS  groups was  determined  by  Student’s  t  test.  The  statistical 
differences between DSS and AMT‐E treated groups were determined by oneway ANOVA followed 
by Bonferroni post‐hoc test. ++ p < 0.01 vs. Sham group. * p < 0.05 and ** p < 0.01 vs. DSS group. 
. - - 1- - t l t i - i i t ti l i t i l l
f X-2 and iNOS enzymes in DSS-induced colitis. (a) Representative western blot analysis of COX-2
(n = 5) a d iNOS (n = 4) proteins; (b) Densitometric data were studied following normaliz tion t the
contr l (h usekeeping ge e, β-Actin). Data are expressed as the means ˘ SEM. Statistical significance
between Sham and DSS groups was determined by Student’s t test. The statistical differences between
DSS and AMT-E treated groups were determined by oneway ANOVA followed by Bonferroni post-hoc
test. ++ p < 0.01 vs. Sham group. * p < 0.05 and ** p < 0.01 vs. DSS group.
Mar. Drugs 2016, 14, 149 7 of 14
3. Discussion
IBD is a group of inflammatory conditions of the gastrointestinal tract with the two major types
including ulcerative colitis (UC) and Crohn’s disease (CD). The standard therapy for IBD includes
mainly immunomodulatory agents, although their use entails severe side effects such as hormonal
disturbance, peptic ulcer, liver dysfunction, and psychological problems [18]. Therefore, the need for
alternative therapeutic approaches is an emerging strategy.
Algae have been used in traditional medicine to treat a variety of diseases [19], including
gastrointestinal disorders such as vomiting, haemorrhoids, and dyspepsia [20]. Further, the protective
effects of the alga Sargassum pallidum [21] and of the extracts of the alga Laminaria japonica [20] on
IBD have recently been reported. In this context, the in vitro anti-inflammatory activity detected
for the natural products isolated from the brown alga Cystoseira usneoides [16,17] prompted us to
evaluate the possible beneficial effects of AMT-E, one of the major active meroterpenoids of the
alga, in an experimental model of colitis. The results have demonstrated that the treatment with this
compound protected mice from the severity of DSS-induced colitis.
The DSS model mimics many of the features of human UC, such as diarrhoea, bloody
faeces, body weight loss, mucosal ulceration, and shortening of colon length [22]. In the current
study, based in an induction of damage by DSS for seven days and finished on day eight, oral
administration of AMT-E (1, 10, and 20 mg/kg) significantly suppressed DSS-induced colitis,
preventing body weight loss, colon shortening, and the extent of intestinal inflammation, although we
did not observe rectal bleeding in any group assayed, nor differences in diarrheal stool between
groups that received DSS (control and treated). In addition, microscopic analysis of the colon
confirmed data from the macroscopic study, reflecting attenuation of the mucosal disruption
and oedema after treatment with AMT-E. The in vivo anti-inflammatory effects of a few marine
meroterpenoids, including avarol, avarone, and a series of polyprenylhydroquinones, have been
previously demonstrated by using the TPA-induced ear edema or the carrageenan-induced paw
edema experimental models [23–26]. More recently, the effects on experimental IBD have been
described for bolinaquinone [27], a sesquiterpene quinone isolated from a sponge of the genus Dysidea,
and zonarol [28], a sesquiterpene hydroquinone isolated from the brown alga Dictyopteris undulata
(Figure 7). In particular, zonarol has been described to protect mice against DSS-induced UC via
the inhibition of both inflammation and apoptosis. In agreement with our findings, zonarol-treated
mice (20 mg/kg/day) also exhibited significantly suppressed DSS-induced colon shortening [28].
On the other hand, bolinaquinone (20 mg/kg/day) was found to protect mice against trinitrobenzene
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shortening [28]. On the other hand, bolinaquinone (20 mg/kg/day) was found to pro ect mice against 






physical barrier  that protect  the  intestinal  epithelial  layer  from  injurious  luminal  stimulants  [29]. 
Altered goblet  cell physiology  is  considered as a hallmark of  IBD pathology  [4]. Further, clinical 
trials have indicated that IBD patients have decreased numbers of goblet cells and reduced mucus 
thickness [30]. The histological findings from our study revealed mucin‐depleted crypts in mice with 
DSS‐induced  colitis,  as  attested  by  the  loss  of  Alcian  blue‐stained  goblet  cells.  Interestingly, 
fl
.
Intestinal goblet cells produce the intestinal mucus, formed mainly by mucus glycoproteins or
mucins. The intestinal mucus layer completely fills the crypts and acts both as a lubricant and as
a physical barrier that protect the intestinal epithelial layer from injurious luminal stimulants [29].
Altered goblet cell physiology is considered as a hallmark of IBD pathology [4]. Further, clinical
trials have indicated that IBD patients have decreased numbers of goblet cells and reduced mucus
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thickness [30]. The histological findings from our study revealed mucin-depleted crypts in mice with
DSS-induced colitis, as attested by the loss of Alcian blue-stained goblet cells. Interestingly, treatments
with AMT-E allows an accumulation of mucus inside goblet cells, which suggests a protective effect of
this compound on the colonic epithelial damage that occurs in colitis. Our results are in line with those
reported for bolinaquinone, which given at a dose of 20 mg/kg ameliorated the signs of TNBS-induced
colitis, as assessed by histological examination of the colon [27]. However, the sesquiterpene
hydroquinone zonarol did not significantly affect the number or size of mucus-producing goblet
cells, as confirmed by Alcian blue or PAS staining [28].
In IBD, the disruption of the epithelial barrier implies the deregulation of the innate immune
system by commensal flora, but also defects in the adaptive immune system [22]. One of the most
prominent histological features observed in IBD is neutrophil infiltration into the inflamed mucosa and
subsequently into the intestinal lumen, resulting in the formation of the so-called crypt abscesses [31].
During intestinal inflammation, neutrophils also contribute to the recruitment of other immune cells
and facilitate mucosal healing by releasing inflammatory cytokines necessary for the resolution of
inflammation [32]. In the present study, we have shown that MPO activity, an index of tissue-associated
neutrophil accumulation, was significantly increased in the colonic mucosa after DSS administration.
However, oral administration of AMT-E ameliorated polymorphonuclear infiltration into the colon,
as evidenced by the suppression of colonic MPO activity as well as the improvement of histological
features. These results suggest that inhibition of neutrophil accumulation by this meroterpene may be
one of the protective mechanisms involved in reducing DSS-induced colonic mucosal injury.
To better understand the mechanism by which AMT-E ameliorates the DSS-induced colitis,
we assessed the colonic production of the inflammatory cytokines TNF-α and IL-1β and the
anti-inflammatory cytokine IL-10. Pro-inflammatory cytokines are known to play a pivotal role
in the initiation and progression of the intestinal mucosa inflammation and immunity in IBD [33].
TNF-α may contribute to the induction of adhesion molecules and the expression of chemokines,
resulting in an influx of inflammatory cells. Anti-TNF-α strategies are largely used in the clinical
treatment of IBD [34], and the emerging data indicate that early use of anti-TNF-α antibodies leads to
better long-term outcome in IBD patients by preventing mucosal damage [22,35]. The significance of
increased IL-1β secretion in IBD has been also well-documented, and increased levels of IL-1β mRNA
have been implicated in the production of many other inflammatory cytokines and also in the majority
of IBD patients [36,37]. In the present study, the administration of AMT-E potently down-regulated
the expression of these pro-inflammatory cytokines. Our results on the anti-inflammatory capacity of
AMT-E are related to previous findings for zonarol, which has also been shown to inhibit the production
of the pro-inflammatory cytokine TNF-α in DSS mice [28], and bolinaquinone, which was found to
reduce the levels of IL-1β in the TNBS model of intestinal damage [27]. Concerning IL-10, this cytokine
is an essential immune component in the intestinal tract, down-regulating the inflammatory process
and helping to restore tissue homeostasis [38]. In animal models, a paper by Kuhn et al. [39] reported
that IL-10-deficient mice developed chronic enterocolitis that can be prevented by administration of
IL-10. Our group has also observed in this type of mice the spontaneous develop of chronic colitis and
adenocarcinoma through a dysplasia sequence [40], and the reversal effects of experimental colitis
by different treatments [41,42]. In the present study, the levels of IL-10 in the colon were found to be
significantly increased in DSS mice and reduced in animals with higher doses, comparable to sham.
This response suggests that the lower presence of pro-inflammatory cytokines by treatment do not
trigger IL-10 production, and confirms less inflammation and lower hyperactive immune response.
Previous research on IBD has demonstrated that Th1/Th2 derived cytokines not only regulate
their own synthesis, but also the expression of mediators and enzymes, including cyclooxygenase-2
(COX-2) and inducible nitric oxide synthase (iNOS) [5]. COX-2 and iNOS enzymes represent important
molecular targets in IBD prevention and treatment. In active inflammation, cell destruction and
increased permeability allow bacteria to enter the lamina propria. Inflammatory cytokines and bacterial
antigens induce and drive the transcription of both COX-2 and iNOS. These two pro-inflammatory
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enzymes are also up-regulated in experimental colitis [42] and in active human IBD [43]. The expression
and activity of these enzymes is associated with disease severity and involves them as potential
anti-inflammatory drug targets. Our data clearly demonstrated that the colonic damage was associated
with a higher expression of both COX-2 and iNOS proteins that were clearly reduced by AMT-E
treatment. In line with our results, the marine meroterpenoid bolinaquinone has been reported to
inhibit COX-2 and iNOS expression [27], while zonarol has only been shown to decrease the levels of
iNOS expression in mice with DSS-induced UC [28].
In summary, our results have demonstrated for the first time that AMT-E, a natural product
isolated from the alga C. usneoides, is effective in the protection against experimental colitis.
The beneficial effects are mainly associated with macroscopic and microscopic data, and also with the
markers of inflammation studied. Future studies are ensured, depending on the availability of AMT-E
that will investigate deeper into the molecular mechanism by which AMT-E decreases intestinal
inflammation as well as into the preventive ability of the compound in a nutraceutical approach,
or the responses in chronic intestinal inflammation models. In any case, the set of effects allows us to
assess the in vivo pharmacological properties of AMT-E, providing valuable information toward the




Seven-week-old female C57BL/6 mice weighing 18–20 g were purchased from Janvier Labs
(France). Mice were housed on a regular 12 h light-dark cycle in a temperature (24–25 ˝C) and
humidity (70%–75%) controlled room, and acclimated for 7 days. They were allowed free access to
a laboratory diet (Panlab, Barcelona, Spain) and water ad libitum. The care and use of the animals
and experimental protocol were approved by the Guidelines for the Animal Ethics Committee of
the University of Seville, and all experiments in this study were carried out in accordance with the
recommendations of the European Union regarding animal experimentation (Directive of the European
Council 2010/63/EU).
4.2. Isolation of 11-Hydroxy-11-O-Methylamentadione (AMT-E)
The meroditerpene AMT-E was isolated from the brown alga Cystoseira usneoides as previously
described [17]. Briefly, the frozen alga was extracted with methanol, and after evaporation of the
solution under reduced pressure, the aqueous residue was extracted with diethyl ether. The resulting
extract was subjected to column chromatography (CC) on silica gel eluted with a mixture of
n-hexane/diethyl ether (50:50, v/v), diethyl ether, chloroform/methanol mixtures (90:10 and 80:20, v/v),
and finally methanol. The fractions eluted with diethyl ether and chloroform/methanol (90:10, v/v)
were further separated by CC using as eluents n-hexane/ethyl acetate mixtures (80:20 to 30:70, v/v),
ethyl acetate, and finally methanol. Selected fractions were subjected to repeated separations in normal
phase HPLC using as eluent n-hexane/ethyl acetate (60:40, v/v) and in reversed phase HPLC using as
eluent methanol/water (70:30, v/v). The isolated compound was identified from its 1H and 13C NMR
spectra [16].
4.3. Induction of DSS Colitis and Treatments
Experimental colitis was induced by giving mice drinking water ad libitum containing 3% (w/v)
DSS for 7 days. Mice of each of the groups were monitored carefully every day to confirm that
they consumed an approximately equal volume of DSS-containing water. Animal body weights and
water and food intake were recorded daily throughout all the experiments. On termination of the
experiment on day eight, mice were killed by cervical dislocation. Colons were removed aseptically,
slightly cleaned in physiological saline to remove faecal residues, weighed, and measured. Afterwards,
Mar. Drugs 2016, 14, 149 10 of 14
the excised colons were cut longitudinally and small pieces from the middle to distal colon (areas
of visible and inflammatory damage) were blotted dry, immediately frozen with liquid nitrogen,
and stored at ´80 ˝C until use.
Mice were divided randomly into five groups (twelve animals per group): (i) Sham group, which
received drinking water, without DSS, throughout the experimental period (Sham); (ii) control group
of induced colitis by DSS (DSS), and (iii–v) DSS groups treated with the compound AMT-E once
a day during the 7 days at the doses of 1, 10 and 20 mg/ kg body weight and named AMT-E (1),
AMT-E (10) and AMT-E (20), respectively. AMT-E was dissolved in vehicle consisting of 0.9% saline
solution and 1% Tween-80 (Sigma-Chemical Co., St. Louis, MO, USA) and was administered by
oral gavage. Both Sham and DSS groups received equal vehicle (0.9% saline solution/1% Tween-80)
on the same schedule as AMT-E. All efforts were made to minimize the animals suffering and to
reduce the number of animals used. The doses of AMT-E were chosen on the basis of literature with
marine meroterpenoids in animal models of inflammation [23,27], including intestinal inflammation
by DSS [28], and also in a short-preliminary experiment in our lab to acquire safety and efficacy in
the DSS model of colitis. Criteria about potential translation of results from animal to humans were
considered [44].
4.4. Histological Studies
For histological examination (4 animals per group), small sections (1 cm, approximately) from
the middle to distal colon were excised and fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS, pH 7.4), dehydrated by increasing concentrations of ethanol, and embedded in paraffin.
Thereafter, sections of tissue were cut at 5 µm on a rotary microtome (Leica Microsystems, Wetzlar,
Germany), mounted on clean glass slides and dried overnight at 37 ˝C. Sections were cleared, hydrated,
and stained with haematoxylin and eosin, and Alcian blue for histological evaluation of colonic
damage and mucus content, respectively, according to standard protocols; slides were coded to
prevent observer bias during evaluation. All tissue sections were examined in an Olympus BH-2
microscope (GMI, Ramsey, MN, USA) for characterization of histopathology changes. The tissues were
analysed by a blinded observer to establish a composite Histological Score as previously described [6],
where researchers do not know the origin of the sample, except the coordinator. Criteria included
mucosal architecture (0, absent; 1, mild; 2, medium; 3, severe), cellular infiltration (0, none; 1, infiltrate
around the crypt basis; 2, infiltrate reaching the muscularis mucosae; 3, infiltrate reaching the
submucosa), and goblet cell depletion (0, absent; 1, present). The results were expressed as the
average scores of the 3 colonic sections.
4.5. Myeloperoxidase Activity Assay
Myeloperoxidase (MPO) is an enzyme found in neutrophils and, in much smaller quantities,
in monocytes and macrophages. The MPO activity according to the method of Grisham et al. [45]
was used as a convenient and valuable tool for evaluating neutrophil infiltration in the colon tissue.
The colonic tissue samples were thawed, weighed, and homogenized in 10 volumes of 50 mM PBS,
pH 7.4. The homogenate was centrifuged at 20,000ˆ g for 20 min at 4 ˝C. The pellet was again
homogenized in 10 volumes 50 mM PBS at pH 6.0, containing 0.5% hexadecyl trimethylammonium
bromide (HETAB) and 10 mM EDTA. This homogenate was subjected to three cycles of
freezing/thawing and a brief period of sonication. About 50 µL of homogenate sample was
added to a 96-well microplate and incubated at 37 ˝C for 3 min with a mixture containing 0.067%
O-dianisidine dihydrochloride, 0.5% HETAB, and 0.3 mM hydrogen peroxide. The changes in
absorbance at 655 nm were measured with a microplate reader (Labysistem Multiskan EX, Helsinki,
Finland). One unit of MPO activity was defined as the amount of enzyme present that produced
a change in absorbance of 1.0 U/min at 37 ˝C in the final reaction volume containing the acetate.
The results were expressed as U/mg tissue.
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4.6. Cytokines Assay
Colonic samples for cytokine determinations (TNF-α, IL-1β, and IL-10) were weighed and
homogenized at 4 ˝C after thawing, in a lysis buffer (1:5 w/v) containing PBS (pH 7.2), 1% bovine serum
albumin (BSA), 0.01 mg/mL leupeptin, 0.01 mg/mL pepstatin, 0.01 mg/mL aprotinin, and 1 mM
phenylmethylsulfonyl fluoride (PMSF). Then, the tubes were centrifugated at 12,000ˆ g for 10 min
at 4 ˝C; the supernatants were frozen at ´80 ˝C until assay. Cytokines levels in frozen colonic tissue
biopsy samples were measured with a commercially available ELISA kit (Diaclone, Besançon, France)
according to the manufacturer’s instructions and then were expressed as nanograms per milligram
of tissue.
4.7. Extraction of Cytoplasmic Proteins and Western Blot Analysis
Frozen colonic tissues were weighed and homogenized in ice-cold lysis buffer (50 mM Tris
HCl, pH 7.5, 8 mM MgCl2, 5 mM ethylene glycol bis (2-aminoethyl ether)-N,N,N1N1-tetraacetic acid
(EGTA), 0.5 mM EDTA, 0.01 mg/mL leupeptin, 0.01 mg/ml pepstatin, 0.01 mg/mL aprotinin, 1 mM
PMSF, and 250 mM NaCl). Homogenates were incubated for 10 min on ice and centrifuged (12,000ˆ g
for 15 min at 4 ˝C), and the supernatants were collected and stored at ´80˝C. Protein concentration
in the supernants was determined following colorimetric method of Bradford with gamma globulin
as the standard [46]. Equal amounts of protein (50 µg) were then separated on 10% acrylamide gel
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. In the next step, the proteins were
electrophoretically transferred onto nitrocellulose membrane at 120 mA for 90 min. The membranes
were then blocked in PBS-Tween 20 containing 5% w/v defatted milk. Later, the membranes were
incubated with specific primary antibodies, rabbit anti-COX-2 and anti-iNOS (Cayman Chemical,
Ann Arbour, MI, USA), at 4 ˝C overnight and 1:1000 dilution. To prove equal loading, the blots
were analysed for β-actin expression using an anti-β-actin antibody (Sigma-Aldrich, St. Louis,
MO, USA). Each membrane was washed three times for 15 min and incubated with the secondary
horseradish peroxidase-linked anti-rabbit (Pierce Chemical, Rockford, IL, USA) for 60 min at room
temperature. After washing the membranes again three times, the immunodetection was performed
using an enhanced chemiluminescence light-detecting kit (Super-Signal West Pico Chemiluminescent
Substrate, Pierce, IL, USA). Densitometric data were studied following normalization to the control
(house-keeping gene). The signals were analysed and quantified with Scientific Imaging Systems
(Biophotonics Image J Analysis Software).
4.8. Statistical Analysis
All data are expressed as arithmetic means ˘ standard error of the mean (S.E.M.) Data were
evaluated with GraphPad Prism® Version 5.00 software. The statistical significance of any difference
in each parameter among the groups was evaluated by one-way analysis of variance (ANOVA)
followed by Tukey test. p values of <0.05 were considered statistically significant. In the experiment
involving histology, the figures shown are representative of at least three experiments performed on
different days.
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